{"analyses":[{"ciLowerLimit":"-2.5","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"-1.1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"Model included treatment+visit+treatment by visit interaction+stratification factor for region (U.S. versus non-U.S.) and tumor location (lower limb/all other) based on IRT+Worst Stiffness NRS baseline value.","paramType":"LS Mean Difference","paramValue":"-1.8","statisticalMethod":"Mixed model repeated measures"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.24","value":"-2.1"},{"groupId":"OG001","spread":"0.28","value":"-0.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"description":"The Worst Stiffness NRS is a single question that asks the participant to assess their worst stiffness in the last 24 hours. Participants rate their worst stiffness on a scale of 0 to 10, where 0 is \"no stiffness\" and 10 is \"worst imaginable.\" Lower scores represented better level of stiffness.","dispersionType":"Standard Error","groups":[{"description":"Participants received 30 mg BIW vimseltinib for 24 weeks.","id":"OG000","title":"Vimseltinib"},{"description":"Participants received matching placebo BIW for 24 weeks.","id":"OG001","title":"Placebo"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The ITT Set consisted of participants who were randomized to a study treatment regimen. Here, \"Overall Number of Participants Analyzed\" is the number of participants evaluable for this outcome measure at the specified time point.","reportingStatus":"POSTED","timeFrame":"Baseline to Week 25 (Cycle 7, Day 1)","title":"Change From Baseline in the Worst Stiffness Numeric Rating Scale (NRS) Score at Week 25","type":"SECONDARY","unitOfMeasure":"score on a scale"}